Century Current Deferred Revenue vs Capex To Revenue Analysis

IPSC Stock

USD 0.91 0.03 3.19%

Century Therapeutics financial indicator trend analysis is way more than just evaluating Century Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Century Therapeutics is a good investment. Please check the relationship between Century Therapeutics Current Deferred Revenue and its Capex To Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Century Stock refer to our How to Trade Century Stock guide.

Current Deferred Revenue vs Capex To Revenue

Current Deferred Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Century Therapeutics Current Deferred Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Century Therapeutics' Current Deferred Revenue and Capex To Revenue is -0.39. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Century Therapeutics, assuming nothing else is changed. The correlation between historical values of Century Therapeutics' Current Deferred Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Century Therapeutics are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Current Deferred Revenue i.e., Century Therapeutics' Current Deferred Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.39

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Century Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Century Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Century Stock refer to our How to Trade Century Stock guide.At present, Century Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting.

	2022	2023	2024	2025 (projected)
Cost Of Revenue	10.1M	13.0M	11.7M	11.2M
Research Development	107.2M	92.7M	106.6M	55.0M

Cost Of Revenue Research Development

Century Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Inventory	Other Current Assets	Total Liab	Intangible Assets	Property Plant Equipment	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total
Total Assets		0.93	0.94	0.87	-0.17	0.91	-0.71	0.7	0.85	0.92	0.79	0.85	0.88	0.96	-0.25	-0.27	-0.43	0.3	-0.28	-0.31	-0.19	-0.43	-0.25	-0.25	-0.22	0.12
Other Current Liab	0.93		0.99	0.68	-0.4	0.95	-0.9	0.62	0.88	1.0	0.6	0.93	0.97	0.98	-0.55	-0.56	-0.55	0.54	-0.56	-0.6	-0.5	-0.58	-0.53	-0.4	-0.53	0.37
Total Current Liabilities	0.94	0.99		0.66	-0.41	0.98	-0.88	0.71	0.93	0.99	0.6	0.96	0.93	0.99	-0.56	-0.57	-0.56	0.56	-0.57	-0.61	-0.5	-0.59	-0.54	-0.41	-0.54	0.37
Total Stockholder Equity	0.87	0.68	0.66		0.12	0.61	-0.38	0.45	0.51	0.65	0.88	0.48	0.67	0.72	0.22	0.15	-0.18	-0.07	0.19	0.16	0.24	-0.19	0.19	0.03	0.22	-0.32
Other Liab	-0.17	-0.4	-0.41	0.12		-0.45	0.55	-0.38	-0.44	-0.44	0.21	-0.38	-0.35	-0.3	0.8	0.86	0.75	-0.94	0.76	0.72	0.74	0.72	0.82	0.87	0.75	-0.28
Accounts Payable	0.91	0.95	0.98	0.61	-0.45		-0.84	0.83	0.98	0.95	0.59	0.96	0.85	0.97	-0.56	-0.57	-0.56	0.58	-0.57	-0.59	-0.51	-0.57	-0.55	-0.44	-0.54	0.35
Cash	-0.71	-0.9	-0.88	-0.38	0.55	-0.84		-0.47	-0.79	-0.91	-0.42	-0.86	-0.89	-0.86	0.71	0.76	0.44	-0.65	0.72	0.76	0.79	0.59	0.73	0.46	0.79	-0.48
Other Assets	0.7	0.62	0.71	0.45	-0.38	0.83	-0.47		0.88	0.63	0.48	0.74	0.43	0.69	-0.36	-0.36	-0.48	0.45	-0.36	-0.33	-0.24	-0.39	-0.35	-0.42	-0.27	0.14
Long Term Debt	0.85	0.88	0.93	0.51	-0.44	0.98	-0.79	0.88		0.89	0.51	0.96	0.75	0.91	-0.57	-0.58	-0.56	0.57	-0.59	-0.62	-0.53	-0.6	-0.56	-0.43	-0.56	0.37
Inventory	0.92	1.0	0.99	0.65	-0.44	0.95	-0.91	0.63	0.89		0.57	0.94	0.96	0.98	-0.58	-0.6	-0.58	0.58	-0.6	-0.64	-0.54	-0.61	-0.57	-0.43	-0.57	0.39
Other Current Assets	0.79	0.6	0.6	0.88	0.21	0.59	-0.42	0.48	0.51	0.57		0.48	0.57	0.68	0.25	0.21	0.15	-0.19	0.26	0.23	0.18	0.09	0.24	0.19	0.19	-0.25
Total Liab	0.85	0.93	0.96	0.48	-0.38	0.96	-0.86	0.74	0.96	0.94	0.48		0.85	0.95	-0.64	-0.62	-0.52	0.56	-0.67	-0.7	-0.58	-0.54	-0.62	-0.4	-0.62	0.54
Intangible Assets	0.88	0.97	0.93	0.67	-0.35	0.85	-0.89	0.43	0.75	0.96	0.57	0.85		0.93	-0.5	-0.54	-0.49	0.49	-0.55	-0.57	-0.48	-0.55	-0.53	-0.37	-0.51	0.33
Property Plant Equipment	0.96	0.98	0.99	0.72	-0.3	0.97	-0.86	0.69	0.91	0.98	0.68	0.95	0.93		-0.46	-0.48	-0.47	0.45	-0.49	-0.53	-0.42	-0.52	-0.46	-0.32	-0.46	0.31
Net Tangible Assets	-0.25	-0.55	-0.56	0.22	0.8	-0.56	0.71	-0.36	-0.57	-0.58	0.25	-0.64	-0.5	-0.46		0.94	0.68	-0.91	0.97	0.96	0.9	0.62	0.94	0.71	0.92	-0.78
Property Plant And Equipment Net	-0.27	-0.56	-0.57	0.15	0.86	-0.57	0.76	-0.36	-0.58	-0.6	0.21	-0.62	-0.54	-0.48	0.94		0.69	-0.92	0.96	0.95	0.93	0.76	0.99	0.75	0.95	-0.56
Net Debt	-0.43	-0.55	-0.56	-0.18	0.75	-0.56	0.44	-0.48	-0.56	-0.58	0.15	-0.52	-0.49	-0.47	0.68	0.69		-0.84	0.69	0.68	0.46	0.86	0.66	0.77	0.52	-0.28
Retained Earnings	0.3	0.54	0.56	-0.07	-0.94	0.58	-0.65	0.45	0.57	0.58	-0.19	0.56	0.49	0.45	-0.91	-0.92	-0.84		-0.89	-0.86	-0.79	-0.77	-0.9	-0.82	-0.82	0.47
Non Current Assets Total	-0.28	-0.56	-0.57	0.19	0.76	-0.57	0.72	-0.36	-0.59	-0.6	0.26	-0.67	-0.55	-0.49	0.97	0.96	0.69	-0.89		0.98	0.89	0.67	0.98	0.71	0.91	-0.74
Non Currrent Assets Other	-0.31	-0.6	-0.61	0.16	0.72	-0.59	0.76	-0.33	-0.62	-0.64	0.23	-0.7	-0.57	-0.53	0.96	0.95	0.68	-0.86	0.98		0.93	0.74	0.94	0.63	0.95	-0.74
Cash And Short Term Investments	-0.19	-0.5	-0.5	0.24	0.74	-0.51	0.79	-0.24	-0.53	-0.54	0.18	-0.58	-0.48	-0.42	0.9	0.93	0.46	-0.79	0.89	0.93		0.63	0.9	0.56	1.0	-0.64
Net Receivables	-0.43	-0.58	-0.59	-0.19	0.72	-0.57	0.59	-0.39	-0.6	-0.61	0.09	-0.54	-0.55	-0.52	0.62	0.76	0.86	-0.77	0.67	0.74	0.63		0.69	0.64	0.67	-0.16
Common Stock Total Equity	-0.25	-0.53	-0.54	0.19	0.82	-0.55	0.73	-0.35	-0.56	-0.57	0.24	-0.62	-0.53	-0.46	0.94	0.99	0.66	-0.9	0.98	0.94	0.9	0.69		0.76	0.91	-0.6
Common Stock Shares Outstanding	-0.25	-0.4	-0.41	0.03	0.87	-0.44	0.46	-0.42	-0.43	-0.43	0.19	-0.4	-0.37	-0.32	0.71	0.75	0.77	-0.82	0.71	0.63	0.56	0.64	0.76		0.57	-0.29
Short Term Investments	-0.22	-0.53	-0.54	0.22	0.75	-0.54	0.79	-0.27	-0.56	-0.57	0.19	-0.62	-0.51	-0.46	0.92	0.95	0.52	-0.82	0.91	0.95	1.0	0.67	0.91	0.57		-0.66
Non Current Liabilities Total	0.12	0.37	0.37	-0.32	-0.28	0.35	-0.48	0.14	0.37	0.39	-0.25	0.54	0.33	0.31	-0.78	-0.56	-0.28	0.47	-0.74	-0.74	-0.64	-0.16	-0.6	-0.29	-0.66

Click cells to compare fundamentals

Century Therapeutics Account Relationship Matchups

Century Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	106.8M	437.4M	486.5M	360.7M	324.6M	352.6M
Other Current Liab	3.8M	6.4M	10.2M	9.2M	8.3M	7.9M
Total Current Liabilities	12.1M	15.7M	29.8M	17.8M	16.1M	15.3M
Total Stockholder Equity	(106.4M)	396.2M	302.7M	184.8M	212.5M	192.9M
Accounts Payable	8.1M	7.6M	5.5M	2.7M	2.5M	2.3M
Cash	27.2M	56.4M	84.3M	47.3M	54.4M	44.2M
Other Assets	2.1M	3.5M	3.2M	1.0	0.9	0.86
Other Current Assets	3.0M	5.0M	3.4M	4.3M	4.9M	4.0M
Total Liab	213.2M	41.1M	183.8M	175.9M	158.3M	212.3M
Property Plant And Equipment Net	15.4M	69.8M	111.7M	92.1M	105.9M	64.1M
Net Debt	(5.7M)	(33.0M)	(34.9M)	847K	974.1K	1.0M
Retained Earnings	(292.3M)	(388.2M)	(519.1M)	(655.8M)	(590.2M)	(619.7M)
Non Current Assets Total	28.0M	209.2M	166.8M	183.7M	211.3M	130.8M
Non Currrent Assets Other	1.2M	3.5M	3.2M	2.5M	2.9M	2.4M
Cash And Short Term Investments	75.8M	222.9M	315.5M	172.7M	198.6M	191.0M
Net Receivables	908K	250K	780K	665K	764.8K	599.7K
Short Term Investments	48.5M	166.4M	231.2M	125.4M	144.2M	134.0M
Liabilities And Stockholders Equity	106.8M	437.4M	486.5M	360.7M	414.8M	326.1M
Non Current Liabilities Total	201.1M	25.5M	154.0M	158.1M	142.3M	114.9M
Capital Lease Obligations	11.9M	14.6M	39.2M	48.2M	55.4M	58.2M
Other Stockholder Equity	185.9M	785.0M	824.3M	840.4M	966.5M	572.6M
Net Invested Capital	(96.7M)	405.1M	313.0M	184.8M	212.5M	157.1M
Long Term Investments	1.1M	135.9M	51.9M	89.1M	102.5M	62.0M
Property Plant And Equipment Gross	15.4M	58.0M	82.8M	114.9M	132.2M	138.8M
Total Current Assets	78.8M	228.2M	319.7M	177.0M	203.5M	195.3M
Net Working Capital	66.7M	212.5M	289.9M	159.1M	183.0M	178.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:

How To Invest In Century

Details

Is Century Stock a good investment?

Details

What is Century Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Century Stock refer to our How to Trade Century Stock guide.

You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.84)

Revenue Per Share

0.037

Quarterly Revenue Growth

4.345

Return On Assets

(0.21)

Return On Equity

(0.63)

The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Century Current Deferred Revenue vs Capex To Revenue Analysis

Current Deferred Revenue vs Capex To Revenue

Current Deferred Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Capex To Revenue

Century Therapeutics fundamental ratios Correlations

Century Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Century Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Inventory	+ 1.0	Other Current Liab
Short Term Investments	+ 1.0	Cash And Short Term Investments
Total Current Liabilities	+ 0.99	Other Current Liab
Inventory	+ 0.99	Total Current Liabilities
Property Plant Equipment	+ 0.99	Total Current Liabilities
Common Stock Total Equity	+ 0.99	Property Plant And Equipment Net

Retained Earnings	- 0.94	Other Liab
Retained Earnings	- 0.92	Property Plant And Equipment Net
Retained Earnings	- 0.91	Net Tangible Assets
Inventory	- 0.91	Cash
Common Stock Total Equity	- 0.9	Retained Earnings
Cash	- 0.9	Other Current Liab